References
- Banjo, O. C., Nadler, R., & Reiner, P. B. (2010). Physician attitudes towards pharmacological cognitive enhancement: Safety concerns are paramount. PLoS One, 5(12), e14322. doi:10.1371/journal.pone.0014322
- Bostrom, N., & Sandberg, A. (2009). Cognitive enhancement: Methods, ethics, regulatory challenges. Science and Engineering Ethics, 15, 311–341.10.1007/s11948-009-9142-5
- Cakic, V. (2009). Smart drugs for cognitive enhancement: Ethical and pragmatic considerations in the era of cosmetic neurology. Journal of Medical Ethics, 35, 611–615.10.1136/jme.2009.030882
- Dresler, M., Sandberg, A., Ohla, K., Bublitz, C., Trenado, C., … Repantis, D. (2013). Non-pharmacological cognitive enhancement. Neuropharmacology, 64, 529–543.10.1016/j.neuropharm.2012.07.002
- Farah, M., Illes, J., Cook-Deegan, R., Gardner, H., Kandel, E., King, P., … Wolpe, P. R. (2004). Neurocognitive enhancement: What can we do and what should we do? Nature Reviews Neuroscience, 5, 421–425.10.1038/nrn1390
- Finger, G., Silva, E. M., & Falavigna, A. (2013). Use of methylphenidate among medical students: A systematic review. Revista da Associação Médica Brasileira, 59, 285–289.10.1016/j.ramb.2012.10.007
- Greely, H., Sahakian, B., Harris, J., Kessler, R. C., Gazzaniga, M., Campbell, P., & Farah, M. J. (2008). Towards responsible use of cognitive-enhancing drugs by the healthy. Nature, 456, 702–705.10.1038/456702a
- Greene, J. D., Sommerville, R. B., Nystrom, L. E., Darley, J. M., & Cohen, J. D. (2001). An fMRI investigation of emotional engagement in moral judgement. Science, 293, 2105–2108.10.1126/science.1062872
- Husain, M., & Mehta, M. A. (2011). Cognitive enhancement by drugs in health and disease. Trends in Cognitive Sciences, 15, 28–36.10.1016/j.tics.2010.11.002
- Hyman, S. E. (2011). Cognitive enhancement: Promises and perils. Neuron, 69, 595–598.10.1016/j.neuron.2011.02.012
- Lynch, G., Cox, C. D., & Gall, C. M. (2014). Pharmacological enhancement of memory or cognition in normal subjects. Frontiers in Systems Neuroscience, 8(90). doi:10.3389/fnsys.2014.00090
- Persson, I., & Savulescu, J. (2008). The perils of cognitive enhancement and the urgent imperative to enhance the moral character of humanity. Journal of Applied Philosophy, 25, 162–177.10.1111/japp.2008.25.issue-3
- Ravnskov, U., Rosch, P. J., Sutter, M. C., & Houston, M. C. (2006). Should we lower cholesterol as much as possible? British Medical Journal, 332, 1330–1332.10.1136/bmj.332.7553.1330
- Reiner, P. (2011). Neuroethics of cognitive enhancement. In MiNDS Optimal Brain Summer Symposium. Hamilton, ON: McMaster University.
- Repantis, D., Schlattmann, P., Laisney, O., & Heuser, I. (2010). Modafinil and methylphenidate for neuroenhancement in healthy individuals: A systematic review. Pharmacological Research, 62, 187–206.10.1016/j.phrs.2010.04.002
- Sanghavi, D. M. (2011). The perils of excessive medical care. The Lancet, 377, 1561–1562.10.1016/S0140-6736(11)60627-2
- Santoni de Sio, F., Faulmüller, N., & Vincent, N. A. (2014). How cognitive enhancement can change our duties. Frontiers in Systems Neuroscience, 8, 131. doi:10.3389/fnsys.2014.00131
- Steiner, H., & Van Waes, V. (2013). Addiction-related gene regulation: Risks of exposure to cognitive enhancers vs. other psychostimulants. Progress in Neurobiology., 100, 60–80.10.1016/j.pneurobio.2012.10.001
- Urban, K. R., & Gao, W. J. (2014). Performance enhancement at the cost of potential brain plasticity: Neural ramifications of nootropic drugs in the healthy developing brain. Frontiers in Systems Neuroscience, 8(38). doi:10.3389/fnsys.2014.00038